Driehaus Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Driehaus Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,633,541	Closed	-$9.51M	–	434
2022 Q3	$9.51M	Buy	+1,633,541	New	+$10.2M	0.14%	201
2018 Q3	–	Sell	-604,596	Closed	-$3.01M	–	591
2018 Q2	$3.01M	Buy	604,596 +24,350	+4%	+$107K	0.1%	223
2018 Q1	$2.26M	Buy	+580,246	New	+$2.04M	0.08%	244
2014 Q2	–	Sell	-3,830	Closed	-$130K	–	695
2014 Q1	$130K	Buy	+3,830	New	+$131K	﹤0.01%	495

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Driehaus Capital Management's CTIC Position: Q4 2022 in Review

Driehaus Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 1,633,541 shares — an estimated $9.51M sold.

Driehaus Capital Management first reported a position in CTIC in Q1 2014 and held it in 4 quarters. The position peaked at $9.51M in Q3 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

Driehaus Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
Driehaus Capital Management sold 1,633,541 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $9.51M.
Driehaus Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 4 quarters.
Driehaus Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $9.51M in Q3 2022.
145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Driehaus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.